Fan Zhen, Schraeder Richard
Department of Pathology, St Joseph Pathology Associates, St Joseph Medical Center, 7601 Osler Drive, Towson, MD 21204, USA.
Surg Oncol Clin N Am. 2011 Oct;20(4):637-53. doi: 10.1016/j.soc.2011.07.004.
Lung cancer classification is of paramount importance in determining the treatment for oncologic patients. Most lung cancers are non-small cell lung carcinomas (NSCLC), which are further subclassified into squamous cell carcinoma, adenocarcinoma, and large cell carcinoma. Lung neuroendocrine tumors are subclassified into typical carcinoid, atypical carcinoid, small cell carcinoma, and large cell neuroendocrine carcinoma. In NSCLC in particular, the histologic classification and tumor mutation analysis are central to today's targeted therapy and personalized treatment. This article discusses the current diagnostic criteria for classification of NSCLC and lung neuroendocrine tumors and implications for oncologic treatment.
肺癌分类对于确定肿瘤患者的治疗至关重要。大多数肺癌是非小细胞肺癌（NSCLC），其进一步细分为鳞状细胞癌、腺癌和大细胞癌。肺神经内分泌肿瘤细分为典型类癌、非典型类癌、小细胞癌和大细胞神经内分泌癌。特别是在NSCLC中，组织学分类和肿瘤突变分析是当今靶向治疗和个性化治疗的核心。本文讨论了NSCLC和肺神经内分泌肿瘤分类的当前诊断标准及其对肿瘤治疗的影响。
